Search Results
Your search for ,aLl matches 18308 pages
Showing 2851 - 2900Neoadjuvant Dual Immunotherapy Plus Chemotherapy Improves Patient Outcomes in Operable Lung Cancer
In the phase II NEOSTAR trial, adding ipilimumab to a neoadjuvant combination of nivolumab plus platinum-based chemotherapy resulted in a major pathologic response in half of all treated patients with early-stage, resectable non–small cell lung cancer (NSCLC). New findings from the NEOSTAR study,...
FDA Approves Dabrafenib/Trametinib for Pediatric Patients With BRAF V600E–Mutated Low-Grade Glioma
On March 16, 2023, the U.S. Food and Drug Administration (FDA) approved dabrafenib (Tafinlar) with trametinib (Mekinist) for pediatric patients aged 1 year and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy. The FDA also approved new oral formulations of both...
Activity of Novel CAR T Cells in Relapsed or Refractory Multiple Myeloma
In a Chinese single-center phase II trial reported in the Journal of Clinical Oncology, Xia et al found that anti–G protein–coupled receptor, class C group 5 member D (GPRC5D) chimeric antigen receptor (CAR) T cells showed activity in patients with relapsed or refractory multiple myeloma. Study...
Addition of Fulvestrant to Alisertib in Endocrine-Resistant Metastatic Breast Cancer
In the phase II TBCRC041 trial reported in JAMA Oncology, Haddad et al found that the addition of fulvestrant to alisertib did not improve objective response rate in postmenopausal patients with HER2-negative, endocrine-resistant metastatic breast cancer. Study Details The multicenter trial,...
Vitamin A and Risk for Pancreatitis During Chemotherapy for ALL
Consuming a diet rich in vitamin A or its analogs may help prevent pediatric and young adult patients with acute lymphoblastic leukemia (ALL) reduce their risk of developing pancreatitis during chemotherapy, according to a recent study by Tsai et al in Science Translational Medicine. Background For ...
Racial Inequalities in Prostate Cancer Care May Be Associated With Facility-Level Disparities
Racial minorities in the United States may be less likely to receive treatment for prostate cancer and, overall, have worse survival outcomes compared with individuals who are White, according to a new study published by Nguyen et al in Urologic Oncology. Typically, patient-level and...
New Research Highlights the Negative Impact of Continued Exclusion of Patients With African Ancestry From Research on Cancer Genomics
Researchers have revealed how the lack of genomic research for individuals with African ancestry—particularly those from the Sub-Saharan region—may be hampering efforts to reduce disparities for patients with prostate cancer, according to a new study published by Gheybi et al in JNCCN–Journal of...
Elizabeth Smyth, MD, Offers Insight on KEYNOTE-859 Findings
The invited discussant of KEYNOTE-859,1 Elizabeth Smyth, MD, consultant in gastrointestinal oncology at Cambridge University Hospitals NHS Foundation Trust in the United Kingdom, called the findings “practice-changing” but cautioned that better patient selection is needed to optimally apply them....
KEYNOTE-859 Interim Analysis: Overall Survival Benefit for First-Line Pembrolizumab in Advanced Gastric Cancer
Results of the interim analysis of KEYNOTE-859 are in, and they confirm the overall survival benefit of first-line immunotherapy plus chemotherapy in advanced gastric cancer.1 Pembrolizumab plus a fluoropyrimidine- and platinum-containing doublet provided a statistically significant improvement in...
Magrolimab Plus Azacitidine in Higher-Risk Myelodysplastic Syndromes
In a phase Ib trial (5F9005) reported in the Journal of Clinical Oncology, David A. Sallman, MD, and colleagues found that the combination of magrolimab and azacitidine showed activity in previously untreated patients with intermediate- to very high–risk myelodysplastic syndromes (MDS). As stated...
Dan T. Vogl, MD, Comments on Follow-up of the UK NCRI Myeloma XI Trial
Dan T. Vogl, MD, Associate Professor of Medicine at the Hospital of the University of Pennsylvania and Director of the Abramson Cancer Center at the Perelman School of Medicine, Philadelphia, told The ASCO Post that the follow-up of the UK NCRI Myeloma XI trial confirms the importance of...
When Can You Stop Lenalidomide Maintenance in Myeloma?
A study aimed at determining the optimal duration of lenalidomide maintenance after autologous stem cell transplantation for multiple myeloma has not answered that question, per se, but has yielded some hints that may inform future clinical trials. The follow-up analysis of the UK NCRI Myeloma XI...
Involving Hospitalists in Inpatient Cancer Care May Reduce Patient Stays, Oncologist Stress
Introducing hospitalists to cancer care comanagement may be associated with decreased lengths of hospital stays for patients, increased inpatient hospital capacity, and reduced stress levels among oncologists—all while maintaining high-quality inpatient care, according to a new study published by...
Delaying Treatment for Patients With Localized Prostate Cancer May Not Increase Mortality Risk, ProtecT Trial Shows
Patients with prostate cancer who undergo active monitoring may experience the same 15-year survival rates as those who undergo radiotherapy or surgery, according to new findings published by Hamdy et al in The New England Journal of Medicine and simultaneously presented at the 2023 European...
Regorafenib, Ipilimumab, and Nivolumab in Microsatellite-Stable Metastatic Colorectal Cancer
In a single-institution phase I trial reported in JAMA Oncology, Marwan Fakih, MD, and colleagues found that the combination of regorafenib, ipilimumab, and nivolumab showed evidence of activity in patients with microsatellite-stable metastatic colorectal cancer who did not have liver metastases....
Hyperfractionated vs Standard-Fractionation IMRT in Locally Advanced, Recurrent Nasopharyngeal Carcinoma
In a Chinese phase III trial reported in The Lancet, You et al found that hyperfractionated vs standard-fractionation intensity-modulated radiotherapy (IMRT) was associated with reduced late severe radiotherapy complications and improved overall survival in patients with locally advanced, recurrent ...
FDA Issues Safety Communication on Reports of Squamous Cell Carcinoma in the Capsule Around Breast Implants
On March 8, the U.S. Food and Drug Administration (FDA) provided an update on reports of squamous cell carcinoma (SCC) in the scar tissue, or capsule, that forms around breast implants. Previously, on September 8, 2022, the FDA released a safety communication informing the public of reports of...
PSMA-PET/CT May Help Improve Clinical Treatment of Prostate Cancer
A trial conducted at the University Hospital Bonn, Germany, has been testing the benefit of PSMA-PET/CT (prostate-specific membrane antigen–positron-emission tomography/computed tomography) to help target where to take biopsy samples, potentially improving the diagnosis of prostate cancer by giving ...
Nirogacestat May Benefit Patients With Desmoid Tumors
As reported in The New England Journal of Medicine by Gounder et al, the phase III DeFi trial has shown significant improvement in progression-free survival with the investigational oral γ-secretase inhibitor nirogacestat vs placebo in patients with desmoid tumors. As noted by the investigators,...
I’m Doing My Part to Erase the Stigma Surrounding Lung Cancer
Ironically, I received a diagnosis of lung cancer when I was feeling my healthiest. In December 2015, when I was just 51 years old, a routine chest x-ray found a small shadow on the lower lobe of my right lung. Despite being a never-smoker, a regular exerciser, and a healthy eater, my primary care...
Cancer Mortality Decreased 33% in Newest Data Reported by the American Cancer Society
Overall cancer mortality rates have decreased 33% since 1991, and cervical cancer incidence decreased 65% from 2012 through 2019, according to the latest statistics reported by the American Cancer Society (ACS).1 Amid this good news, however, was a troubling 3% annual increase in prostate cancer...
Novel Herbal Oncology Program for Management of Cancer Symptoms at an NCI-Designated Cancer Center
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Jun J. Mao, MD, MSCE, Guest Editor of the Integrative Oncology series, and Yen ...
Mirvetuximab Soravtansine Active in Platinum-Resistant Ovarian Cancer With High FRα Expression
As reported in the Journal of Clinical Oncology by Ursula A. Matulonis, MD, of the Dana-Farber Cancer Institute, and colleagues, the phase II SORAYA study has shown activity of mirvetuximab soravtansine-gynx, an antibody-drug conjugate targeting folate receptor α (FRα), in women with...
Unique Challenges of Cancer Care in India
In this installment of The ASCO Post’s Global Oncology, guest editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Rajendra Toprani, MBBS, MS, MCh, Head of the Department of Head and Neck Surgical Oncology at HCG Cancer Centre, Ahmedabad, India. Dr. Toprani’s areas of interest include oral,...
Four Leading UPMC/Pitt Scientists Receive Funding for Research in Breast Cancer
Steffi Oesterreich, PhD, and Adrian V. Lee, PhD, breast cancer researchers at UMPC Hillman Cancer Center and Magee-Womens Research Institute, along with Wendie Berg, MD, PhD, Professor of Radiology at UMPC Magee-Womens Hospital, all of the University of Pittsburgh School of Medicine, have received ...
PhALLCON Study: Ponatinib Superior to Imatinib in Combination With Chemotherapy in Newly Diagnosed, Ph-Positive ALL
Ponatinib appears to be a more effective tyrosine kinase inhibitor than imatinib in newly diagnosed, Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) when combined with reduced-intensity chemotherapy, according to data presented during the ASCO Plenary Series: February 2023...
FDA Updates Mammography Regulations to Require Reporting of Breast Density Information and Enhance Facility Oversight
On March 9, the U.S. Food and Drug Administration (FDA) published updates to the mammography regulations to, among other things, require mammography facilities to notify patients about the density of their breasts, strengthen the FDA’s oversight and enforcement of facilities, and help interpreting...
Omission of Radiotherapy in Children and Adolescents With Early-Stage Classical Hodgkin Lymphoma With Adequate Response to OEPA Chemotherapy
As reported in The Lancet Oncology by Mauz-Körholz et al, children and adolescents with early-stage classical Hodgkin lymphoma enrolled in the EuroNet-PHL-C1 study who had an adequate response to an OEPA chemotherapy regimen (vincristine, etoposide, prednisone, and doxorubicin) and did not receive...
First ASCO Guideline for Immunotherapy and Targeted Therapy in Advanced Gastroesophageal Cancer Now Available
An ASCO expert panel has developed a comprehensive guideline for immunotherapy and targeted therapy in patients with advanced gastroesophageal cancer.1 The guideline is based on the many recent advances in immunotherapy and targeted therapy. “The role of immunotherapy has changed practice in the...
Oncologists Applaud State of the Union’s Focus on Ending Cancer as We Know It
Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of ASCO and the Association for Clinical Oncology, issued the following statement after President Joseph Biden’s State of the Union address on February 7. “ASCO applauds President Biden’s focus on ‘ending cancer as ...
Long-Term Results of European Pediatric Soft-Tissue Sarcoma Study in Nonmetastatic Rhabdomyosarcoma
In an analysis reported in the Journal of Clinical Oncology, Gianni Bisogno, MD, PhD, and colleagues detailed 5-year outcomes among children and adolescents with nonmetastatic rhabdomyosarcoma in the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study. Study Details The RMS2005 study...
Pilot Program Shows Diversity-Focused Clinical Trial Tools Are Useful at Cancer Research Sites
Cancer research sites demonstrated the utility of new resources designed to increase the diversity of participants in cancer clinical trials, although challenges remain, according to two studies published recently in JCO Oncology Practice.1,2 The studies examine the results from a collaborative...
Highlights of the 2022 Annual Conference of the International Society of Geriatric Oncology
The 2022 Annual Conference of the International Society of Geriatric Oncology (SIOG) was held in Geneva, Switzerland, on October 28–30, 2022. The meeting was held in conjunction with the SIOG 2022 Public Policy Meeting: Global Policy to Action on Cancer in the Aging Population at UN Headquarters...
‘Best of SABCS’: Top 7 Picks From the 2022 Meeting by Jame Abraham, MD, FACP
Among the high-quality abstract presentations at the San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCOPost asks our Associate Editor, breast cancer specialist Jame Abraham, MD, FACP, to give us his picks. Dr. Abraham is Chairman of ...
Blood Test May Identify Patients With AML at Greater Risk of Relapse After Bone Marrow Transplant
Researchers have found that screening for residual disease prior to a bone marrow transplant may help physicians identify which adult patients in remission from acute myeloid leukemia (AML) are at risk of relapsing after the procedure, according to a novel study published by Dillon et al in JAMA....
Elacestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
On January 27, 2023, elacestrant was approved by the U.S. Food and Drug Administration (FDA) for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine ...
Novel Immunotherapy Combination Shows Activity in Microsatellite-Stable Metastatic Colorectal Cancer
In heavily pretreated patients with metastatic colorectal cancer who have microsatellite-stable tumors, the novel combination of the monoclonal antibodies botensilimab and balstilimab showed clinical activity, producing durable responses and an estimated 63% overall survival rate at 12 months,...
Expert Point of View: David Wang, MD, PhD
David Wang, MD, PhD, Associate Professor of Internal Medicine at UT Southwestern Medical Center and VA North Texas Health Care System, was invited to discuss the CheckMate 649 and RATIONALE 305 studies. “CheckMate 649 was the first randomized controlled trial to demonstrate a significant survival...
Phase III Trials Confirm Benefit of First-Line Anti–PD-1 Inhibition Plus Chemotherapy in Gastric Cancer
Two phase III trials evaluating the addition of drugs targeting PD-1 to chemotherapy—RATIONALE 305 and CheckMate 649—confirmed the benefit of this approach as first-line therapy for advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma, in findings presented at the 2023 ASCO GI...
Extended Follow-up Supports First-Line Use of Nivolumab Plus Cabozantinib in Advanced Renal Cell Carcinoma
The 3-year follow-up of the phase III CheckMate 9ER trial demonstrates superior outcomes with the combination of nivolumab plus cabozantinib vs the former standard-of-care sunitinib as first-line treatment of advanced or metastatic renal cell carcinoma.1 These benefits were achieved with the...
Improving Physician-Patient Communication
In 2017, ASCO published a new guideline in the Journal of Clinical Oncology outlining the best practices for communicating effectively with patients and their family members.1 The goal of the communication guideline is to provide oncologists with a framework of specific practices to enable them to...
TRITON3 Trial: Rucaparib Extends Progression-Free Survival in Selected Patients With Metastatic Castration-Resistant Prostate Cancer
The poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib prolonged imaging-based progression-free survival vs physician’s choice of therapy in patients with metastatic castration-resistant prostate cancer whose tumors harbored BRCA or ATM alterations. These results of the phase III TRITON3 study ...
Nivolumab Followed by Nivolumab/Ipilimumab Boosting in Nonresponders Among Previously Treated Patients With Advanced Urothelial Carcinoma
In a German-Austrian phase II study (TITAN-TCC) reported in The Lancet Oncology, Grimm et al found that a strategy of nivolumab monotherapy followed by immunotherapeutic boosting including high-dose ipilimumab in nivolumab nonresponders showed activity in patients with unresectable or metastatic...
Expert Point of View: Michiel S. Van der Heijden, MD, PhD
Formal discussant of the CheckMate 274 trial, Michiel S. Van der Heijden, MD, PhD, of the Netherlands Cancer Institute, said it is an “important” study. “In looking at these results, one should consider the goal of adjuvant therapy in this setting. Is overtreatment of patients cured by surgery...
CheckMate 274: Continued Disease-Free Survival Benefits With Adjuvant Nivolumab in High-Risk Urothelial Carcinoma
With longer-term follow-up, adjuvant nivolumab continued to demonstrate improved disease-free survival, non–urothelial tract recurrence–free survival, and distant metastasis–free survival vs placebo in patients with muscle-invasive urothelial carcinoma at high risk of recurrence after surgery,...
Adjuvant Paclitaxel and Trastuzumab in Node-Negative, HER2-Positive Breast Cancer: Long-Term Follow-up
In an analysis reported in The Lancet Oncology, Sara M. Tolaney, MD, MPH, and colleagues described 10-year survival outcomes from the phase II APT trial assessing adjuvant paclitaxel/trastuzumab in patients with node-negative, HER2-positive breast cancer. Study Details The U.S. multicenter trial...
PSA Level at Time of Salvage Radiation Therapy After Radical Prostatectomy and Risk of All-Cause Mortality
In a study reported in the Journal of Clinical Oncology, Derya Tilki, MD, and colleagues identified a prostate-specific antigen (PSA) level cutpoint, above which initiation of salvage radiation therapy after radical prostatectomy was associated with an increased risk of all-cause mortality in...
Depression May Be Linked to Higher Levels of Inflammation, Poorer Outcomes in Patients With Lung Cancer
Patients with lung cancer who have moderate to severe depression may be two to three times more likely to have inflammation levels that predict poor survival rates, according to a new study published by Andersen et al in PLOS One. The findings may help explain why a substantial portion of patients...
Regardless of Income, American Indian/Native American Women May Be Less Likely to Undergo Mammography Than White Women
Investigators found that American Indian/Native American women living in higher-income communities did not have a higher mammography uptake compared with American Indian/Native American women living in lower-income communities, according to a new study published by Christensen et al in the American ...
Researchers Find New Genetic Risk Factors in Large Study of Prostate Cancer in Black Patients
Researchers have identified nine new genetic variants that may increase the risk of developing prostate cancer in Black patients, according to a novel study published by Chen et al in European Urology. The investigators also found that genetic differences may help determine which patients are most...
